This Project Grant award of $614,424 from the National Institute on Aging (CFDA 93.866 Aging Research program) supports research to illuminate early microglial dysfunction in Alzheimer's disease (AD). The study aims to integrate novel explainable AI techniques with deep learning methods to better define AD-specific microglial states and pathways from single-cell brain data. As proof-of-concept, the researchers will model the combined effects of AD stimuli and neuronal injury on...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $126,956 to the University of California, San Diego (UCSD) to conduct research on generating new neurons in the aging adult brain. The key objectives are to: Use single cell spatial transcriptomics to define the cellular pathway and molecular mechanisms underlying the conversion of glial cells into functional replacement neurons in the aged mouse brain. This approach was previously...
This Project Grant award in the amount of $3,929,011 was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to elucidate the role of neuronal dysfunction and hyperexcitability in the early biological progression of Alzheimer's disease (AD). The research team at the University of California, San Francisco (UCSF) will conduct a longitudinal, multimodal neuroimaging study on clinical cohorts of amyloid-beta (Aβ)...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This $372,690 project grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to comprehensively understand the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The principal investigators at the University of California, Berkeley will develop novel statistical methods to uncover how amyloid-beta, tau accumulation, and cognition are causally related in different subpopulations of AD patients. This insight is expected to reveal optimal treatment...
The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
The National Institutes of Health's National Institute on Aging awarded a $7,432,562 project grant to the Regents of the University of California, San Francisco on September 15, 2022 under the Aging Research program (CFDA 93.866). The grant will support research to elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes through 2025. Specifically, the University of California, San Francisco will use CRISPR and single-cell RNA sequencing...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This $3,845,311 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund research at the University of California, San Diego (UCSD) to investigate early determinants of Alzheimer's disease (AD) using patient-derived induced neurons (iNs). The project aims to better understand the mechanisms that cause mild cognitive impairment (MCI) and the progression to AD, integrating multi-omic analysis of MCI patient-specific iNs with polygenic risk scores. The research will assess effects of impaired MCI neurons on human astrocytes and microglia, and analyze how underlying epigenetic landscapes associate with age acceleration and MCI neuronal phenotypes. This comprehensive functional characterization of MCI/AD disease etiology aims to identify new treatment strategies. The award period is from August 15, 2024 to April 30, 2029.